Business Description
Crescita Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA2258471028
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.48 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 4.18 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -0.36 | |||||
Beneish M-Score | -3.96 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.1 | |||||
3-Year EBITDA Growth Rate | -69.7 | |||||
3-Year FCF Growth Rate | -28.7 | |||||
3-Year Book Growth Rate | -2.7 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 0.05 | |||||
9-Day RSI | 3.55 | |||||
14-Day RSI | 13.61 | |||||
6-1 Month Momentum % | -30.33 | |||||
12-1 Month Momentum % | -35.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.8 | |||||
Quick Ratio | 2.54 | |||||
Cash Ratio | 1.93 | |||||
Days Inventory | 290.04 | |||||
Days Sales Outstanding | 66.43 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | 6.58 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 59.15 | |||||
Operating Margin % | -11.16 | |||||
Net Margin % | -11.33 | |||||
FCF Margin % | 11.64 | |||||
ROE % | -9.88 | |||||
ROA % | -7.48 | |||||
ROIC % | -20.05 | |||||
ROC (Joel Greenblatt) % | -22.84 | |||||
ROCE % | -6.81 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 6.3 | |||||
PS Ratio | 0.5 | |||||
PB Ratio | 0.46 | |||||
Price-to-Tangible-Book | 0.52 | |||||
Price-to-Free-Cash-Flow | 4.26 | |||||
Price-to-Operating-Cash-Flow | 4.26 | |||||
EV-to-EBIT | -0.26 | |||||
EV-to-EBITDA | 1.23 | |||||
EV-to-Revenue | 0.02 | |||||
EV-to-FCF | 0.18 | |||||
Price-to-Projected-FCF | 0.36 | |||||
Price-to-Net-Current-Asset-Value | 0.68 | |||||
Price-to-Net-Cash | 2.46 | |||||
Earnings Yield (Greenblatt) % | -384.62 | |||||
FCF Yield % | 24.42 |